PMA device
Symplicity G3 Renal Denervation RF Generator
Medtronic, Inc. · Ablation Catheter, Renal Denervation (QYI, Class III) · First FDA decision Apr 10, 2025, newest Apr 10, 2025High blood pressure (hypertension)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
2
Naming "Symplicity G3"
MAUDE reports
0
Brand "Symplicity G3", since 2015
PubMed studies
0
Mentioning "Symplicity G3"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Symplicity G3 Renal Denervation RF Generator
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- Symplicity G3 Renal Denervation RF Generator; Symplicity Spyral Multi-Electrode Renal Denervation CatheterPMA supplement
P220026-S012 · Decided Apr 10, 2025 · 30 days after receipt · Normal 180 Day Track No User Fee
Device type: Ablation catheter, renal denervation (QYI) · Cardiology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Renal Denervation for Uncontrolled HypertensionNational analysisReview closedCAG-00470NUpdated Sep 22, 2026
- Renal Denervation (RDN) for Uncontrolled HypertensionNational determinationOn the books20.40Updated Mar 24, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Symplicity G3", any status and sponsor, newest update first.
Saskatchewan Health Authority - Regina AreaAcademic, hospital or other
NCT04332731 · 10 participants (planned) · Start Dec 1, 2020 · Primary completion Jul 31, 2024
Device: Symplicity Spyral™ multi electrode renal denervation system · For: Loin Pain-Hematuria Syndrome
Sites: Regina, Canada
- Renal Denervation in Hypertrophic CardiomyopathyStatus unknown
Adolfo FontenlaAcademic, hospital or other
NCT05577208 · 20 participants (planned) · Start Nov 26, 2022 · Primary completion Jun 30, 2024
Device: "Symplicity Spyral" multi-electrode renal denervation catheter and "Symplicity G3" generator (Renal Denervation System) · For: Hypertrophic Cardiomyopathy
Sites: Madrid, Spain
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Symplicity G3", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code QYI
47 reports: 13 malfunction, 33 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Symplicity G3"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code QYI.
- Symplicity Spyral Renal Denervation SystemMedtronic, Inc. · PMA 2026
- Paradise Ultrasound Renal Denervation System (Paradise System)Recor Medical, Inc. · PMA 2026
- Symplicity Spyral Multi-Electrode Renal Denervation CatheterMedtronic, Inc. · PMA 2024
- ReCor Paradise® Ultrasound Renal Denervation SystemRecor Medical, Inc. · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.